Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation

被引:349
|
作者
Kurki, S
Peltonen, K
Latonen, L
Kiviharju, TM
Ojala, PM
Meek, D
Laiho, M
机构
[1] Univ Helsinki, Biomedicum, Haartman Inst, FIN-00014 Helsinki, Finland
[2] Univ Helsinki, Biomedicum, Mol Canc Biol Res Program, FIN-00014 Helsinki, Finland
[3] Univ Helsinki, Cent Hosp, Diagnost Lab, FIN-00014 Helsinki, Finland
[4] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland
基金
芬兰科学院;
关键词
D O I
10.1016/S1535-6108(04)00110-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Nucleophosmin (NPM, B23) is an abundant nucleolar phosphoprotein involved in ribosome biogenesis, and interacts with tumor suppressor proteins p53 and Rb. Here we show that NPM is a UV damage response protein that undergoes nucleoplasmic redistribution and regulates p53 and HDM2 levels and their interaction. By utilizing RNAi approaches and analyses of endogenous and ectopically expressed proteins, we demonstrate that NPM binds HDM2 and acts as a negative regulator of p53-HDM2 interaction. Viral stress, enforced by expression of Kaposi's sarcoma virus K cyclin, causes NPM redistribution, K cyclin-NPM association, and p53 stabilization by dissociation of HDM2-p53 complexes. The results demonstrate novel associations of HDM2 and K cyclin with NPM and implicate NPM as a crucial controller of p53 through inhibition of HDM2.
引用
收藏
页码:465 / 475
页数:11
相关论文
共 50 条
  • [41] N-Acylpolyamine inhibitors of HDM2 and HDMX binding to p53
    Hayashi, Ryo
    Wang, Deyun
    Hara, Toshiaki
    Iera, Jaclyn A.
    Durell, Stewart R.
    Appella, Daniel H.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2009, 17 (23) : 7884 - 7893
  • [42] A Regulatory Loop Composed of RAP80-HDM2-p53 Provides RAP80-enhanced p53 Degradation by HDM2 in Response to DNA Damage
    Yan, Jun
    Menendez, Daniel
    Yang, Xiao-Ping
    Resnick, Michael A.
    Jetten, Anton M.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2009, 284 (29) : 19280 - 19289
  • [43] Terphenyl-based helical mimetics that disrupt the p53/HDM2 interaction
    Yin, H
    Lee, GI
    Park, HS
    Payne, GA
    Rodriguez, JM
    Sebti, SM
    Hamilton, AD
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2005, 44 (18) : 2704 - 2707
  • [44] Therapeutic reactivation of p53 through dual targeting of HDM2 and HDMX with a stapled p53 peptide
    Bernal, Federico
    Wade, Mark
    Wahl, Geoffrey M.
    Walensky, Loren D.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [45] p53 promotes its own polyubiquitination by enhancing the HDM2 and HDMX interaction
    Medina-Medina, Ixaura
    Martinez-Sanchez, Mayra
    Hernandez-Monge, Jesus
    Fahraeus, Robin
    Muller, Petr
    Olivares-Illana, Vanesa
    PROTEIN SCIENCE, 2018, 27 (05) : 976 - 986
  • [46] Targeting p53, hdm2, and CD19: vaccination and immunologic strategies
    Voss, RH
    Lotz, C
    Cellary, A
    Theobald, M
    BONE MARROW TRANSPLANTATION, 2000, 25 (Suppl 2) : S43 - S45
  • [47] RNAi knockdown of HdmX or Hdm2 leads to new insights into p53 signaling
    Berberich, Steven J.
    CELL CYCLE, 2010, 9 (18) : 3640 - 3641
  • [48] Effect of linker on the binding free energy of stapled p53/HDM2 complex
    Im, Haeri
    Ham, Sihyun
    PLOS ONE, 2020, 15 (04):
  • [49] Targeting p53, hdm2, and CD19: vaccination and immunologic strategies
    R-H Voss
    C Lotz
    A Cellary
    M Theobald
    Bone Marrow Transplantation, 2000, 25 : S43 - S45
  • [50] Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells
    Grasberger, BL
    Lu, TB
    Schubert, C
    Parks, DJ
    Carver, TE
    Koblish, HK
    Cummings, MD
    LaFrance, LV
    Milkiewicz, KL
    Calvo, RR
    Maguire, D
    Lattanze, J
    Franks, CF
    Zhao, SY
    Ramachandren, K
    Bylebyl, GR
    Zhang, M
    Manthey, CL
    Petrella, EC
    Pantoliano, MW
    Deckman, IC
    Spurlino, JC
    Maroney, AC
    Tomczuk, BE
    Molloy, CJ
    Bone, RF
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (04) : 909 - 912